Researchers Find Potential for Repurposing Drug to Target Certain Types of Leukemia Cells
Drs. Jha and Maciejewski have identified eltrombopag as a potent inhibitor of specific leukemia cells, which could lead to new drugs that target leukemia cells while preserving and expanding normal blood cells.
Flipping the Switch on Prostate Cancer Immunotherapy
Dr. Nima Sharifi and a team of researchers uncovered how tumors circumvent prostate cancer therapy and identified a potential window of time after treatment when tumors may be responsive to immunotherapy.
Exploring a Blood-Based Biomarker of Inflammation for Alzheimer’s Disease
Dr. Bekris’ team found that patterns of sTREM2-related inflammatory activity were specific to Alzheimer’s disease stages.
Dr. Justin Lathia Named One of Only Nine Recipients of National Research Program Award
Dr. Lathia has received an eight-year, $5.2 million award from the National Institute of Neurological Disorders and Stroke to further research into the dynamics of immune suppression in malignant brain tumors and target future immune-activating therapies.
NIH Grant to Advance the Study of Cholestatic Liver Diseases
Dr. Sakaguchi and his team will investigate the molecular mechanisms and malfunctions of the biliary system to develop new treatments for liver diseases.
New Research Collaborative Aims at Closing Minority Health Disparities
With a Cleveland Clinic research co-laboratories award, Drs. Schmit and Mata will establish the Cleveland Clinic Latino Epidemiology (CCLE) Cohort to help close the gap in research participation and health disparities for the Latino population.
Cleveland Clinic Appoints Ted Ross, PhD, as Global Director of Vaccine Development
Dr. Ross will lead the development of novel vaccine platforms for a variety of infectious diseases, including influenza, HIV and COVID-19.
MCL1 in the Nucleus Appears to Drive Chemoresistance in Colorectal Cancer
Dr. Gastman and collaborators have published findings indicating Bcl-xL inhibitors may help overcome this complication.
The STAR Consortium Awarded $5.3 Million from the Helmsley Charitable Trust to Develop Next Generation Biomarker Tools for Crohn’s Disease Patients
The STAR consortium, led by coordinating PI Dr. Rieder, seeks to identify and develop novel biomarkers to help establish effective therapeutics for Crohn’s disease patients with fibrosis.
First Research Published Using Cleveland Clinic’s COVID-19 Study Samples Provides Glimpse into Potential New Treatments
Dr. Jung and his team of researchers published the novel COVID-19 study, which details the critical role viral gene ORF8 plays in infection and outcomes rates, using samples from Cleveland Clinic’s BioRepository.
Cleveland Clinic Appoints Key Leadership to Center for Immunotherapy & Precision Immuno-Oncology
J. Joseph Melenhorst, PhD, has been appointed director of the new Cell Therapy and Immuno-Engineering Program, and Vice Chair of the Center for Immunotherapy and Precision Immuno-Oncology at Cleveland Clinic.
Characterizing Dermatologic Findings in PTEN Hamartoma Tumor Syndrome
Dr. Eng and colleagues conducted a multi-center analysis of skin findings in patients with PTEN hamartoma tumor syndrome.
Metabolites May Influence Cancer Versus Autism Risk in PTEN Hamartoma Tumor Syndrome
Dr. Eng’s team found that distinct metabolite profiles may be associated with either cancer or autism spectrum disorder and/or developmental delay in individuals with PTEN hamartoma tumor syndrome.
BME Researcher Receives Award from the Clinical Research Forum for Pioneering Bionic Arm Study
Dr. Marasco was honored for engineering a prosthetic that allows the wearer to “think” and function like an able-bodied person.
Prediction Model Aids in the Early Diagnosis of Dravet Syndrome
Dr. Lal and colleagues have developed a statistical model that integrates genetic and clinical data to calculate the probability of developing Dravet syndrome.
Cleveland Clinic Researchers Receive Two Grants to Study Pathogenesis of Multiple Sclerosis
Dr. Dutta is collaborating with other Cleveland Clinic researchers to explore possible novel causes of disease progression in multiple sclerosis, as well as potential therapeutic targets.
New Model May Predict Immunotherapy Response in Melanoma Patients
Dr. Gastman’s team found that high levels of a CD8 T-cell subpopulation may predict immune checkpoint inhibitor therapy resistance in melanoma.
NIH Funds Multi-Institutional Training Network to Support Kidney, Urologic and Hematologic Research
Drs. Sedor and Boron are leading a collaboration of Cleveland biomedical institutions to address gaps in community health and training
Cleveland Clinic Model Predicts the Risk of Hospital Readmissions
Dr. Misra-Hebert and colleagues assessed a Cleveland Clinic model’s ability to predict the likelihood that a patient would need to be readmitted to the hospital within 30 days of discharge.
Lerner-Developed Flow Cytometry Best Practices Lay Groundwork for Global Recommendations
Dr. Asosingh’s team developed new Shared Resource Laboratory (SRL) guidelines, including user consultations, to ensure experimental success and accuracy.
Investigating Age Differences in COVID-19 Immune Response
Dr. Cheng’s team identified several differences in immune and inflammatory responses that may help explain the elevated risk for severe illness and death observed in older COVID-19 patients.
Adaptive Differentiation Drives Cell Repair in Diseased Tissues
Dr. Stappenbeck’s group found a new cell type that is produced by intestinal epithelial stem and progenitor cells and provides rapid structural support to damaged, high-turnover tissue and a foundation for its proper healing.